Challenges and opportunities to the design and implementation of chemoprevention trials for prostate cancer.
Since 1991 and the activation of the Prostate Cancer Prevention Trial as well as similar prevention studies in several other organ sites, the interest in prostate cancer prevention has increased substantially. Despite such interest, the challenges to prevention trials-in design, implementation, prioritization, and allocation of resources-are substantial. Simultaneously, there has been an explosion in new targets and agents that may have an effect in the prevention of this disease. In this manuscript, we discuss these challenges to the study of prostate cancer prevention and provide a blueprint for prioritization of future studies.
Thompson
Ian M
IM
Division of Urology, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA. thompsoni@uthscsa.edu
Basler
Joseph A
JA
Leach
Robin
R
Troyer
Dean
D
Klein
Eric
E
Brawley
Otis
O
D000230:Adenocarcinoma / Q000453:epidemiology / Q000517:prevention & control*; D000328:Adult; D000465:Algorithms; D016588:Anticarcinogenic Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D015415:Biomarkers; D002471:Cell Transformation, Neoplastic; D002986:Clinical Trials as Topic / Q000379:methods* / Q000592:standards / Q000706:statistics & numerical data; D016861:Cyclooxygenase Inhibitors / Q000627:therapeutic use; D006801:Humans; D008297:Male; D018579:Patient Selection; D011471:Prostatic Neoplasms / Q000453:epidemiology / Q000517:prevention & control*; D012107:Research Design; D014810:Vitamin E / Q000627:therapeutic use
D016588:Anticarcinogenic Agents; D015415:Biomarkers; D016861:Cyclooxygenase Inhibitors; D014810:Vitamin E